Liberum Capital restated their buy rating on shares of GlaxoSmithKline plc (LON:GSK) in a research report sent to investors on Wednesday. The firm currently has a GBX 1,760 ($23.23) price target on the stock.
Other equities analysts also recently issued reports about the stock. Bryan, Garnier & Co restated a buy rating and issued a GBX 1,750 ($23.09) target price on shares of GlaxoSmithKline plc in a research note on Thursday, July 20th. Goldman Sachs Group, Inc. (The) restated a buy rating and issued a GBX 1,900 ($25.07) target price on shares of GlaxoSmithKline plc in a research note on Thursday, July 20th. Jefferies Group LLC restated a buy rating and issued a GBX 1,900 ($25.07) target price on shares of GlaxoSmithKline plc in a research note on Thursday, July 13th. Berenberg Bank restated a buy rating and issued a GBX 1,885 ($24.87) target price on shares of GlaxoSmithKline plc in a research note on Wednesday, July 26th. Finally, Investec restated a buy rating and issued a GBX 1,800 ($23.75) target price on shares of GlaxoSmithKline plc in a research note on Wednesday, July 26th. Three analysts have rated the stock with a sell rating, eleven have given a hold rating and six have given a buy rating to the company. GlaxoSmithKline plc has an average rating of Hold and a consensus price target of GBX 1,652.50 ($21.81).
Shares of GlaxoSmithKline plc (GSK) opened at 1366.50 on Wednesday. The stock’s 50 day moving average is GBX 1,491.51 and its 200-day moving average is GBX 1,573.23. The stock’s market capitalization is GBX 66.79 billion. GlaxoSmithKline plc has a 12-month low of GBX 1,351.00 and a 12-month high of GBX 1,724.50.
GlaxoSmithKline plc (LON:GSK) last issued its earnings results on Wednesday, October 25th. The company reported GBX 32.50 ($0.43) EPS for the quarter, topping the Zacks’ consensus estimate of GBX 31.80 ($0.42) by GBX 0.70 ($0.01). The business had revenue of GBX 784.30 billion for the quarter. GlaxoSmithKline plc had a negative net margin of 1.17% and a negative return on equity of 57.19%. On average, analysts expect that GlaxoSmithKline plc will post $110.75 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This piece was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.dispatchtribunal.com/2017/10/28/glaxosmithkline-plc-gsk-earns-buy-rating-from-liberum-capital.html.
In related news, insider Simon Dingemans purchased 1,076 shares of the firm’s stock in a transaction on Thursday, October 12th. The stock was acquired at an average price of GBX 1,527 ($20.15) per share, with a total value of £16,430.52 ($21,681.87). Also, insider Urs Rohner purchased 473 shares of the firm’s stock in a transaction on Wednesday, October 25th. The stock was bought at an average cost of GBX 1,518 ($20.03) per share, with a total value of £7,180.14 ($9,474.98). Insiders have purchased 1,574 shares of company stock valued at $2,398,888 in the last three months.
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.